Mark Bustoros

12PUBLICATIONS
97CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Respiratory diseasesGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jun 09, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur

|Jan 03, 2025
Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

Omar Nadeem, Michelle P Aranha, Robert Redd

|May 22, 2024
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.

Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz

|Feb 14, 2023
Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia.

Mateo Mejia Saldarriaga, Mohammad Alhomoud, Gail Roboz

|Jun 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.

Mark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis

|Dec 04, 2021
Regular Aspirin Use and Mortality in Patients with Multiple Myeloma.

Catherine R Marinac, Dong Hoon Lee, Graham A Colditz

Pageof 2

Frequent Collaborators

5 joint publications

Irene M Ghobrial

3 joint publications

Robert Redd

2 joint publications

P Leif Bergsagel

2 joint publications

Shaji Kumar